Vascular Health
Conditions
Keywords
vascular health, crossover point
Brief summary
Recruit postmenopausal women and randomly assign them to one of four groups: Early Postmenopausal Exercise Group (EE), Late Postmenopausal Exercise Group (LE), Early Postmenopausal Control Group (EC), and Late Postmenopausal Control Group (LC). All participates will undergo a graded exercise test to determine their maximum oxygen uptake, and vascular function response will be measured immediately after the exercise test. The COP exercise intensity for postmenopausal women will be obtained through the exercise test, and subjects in the EE and LE groups will undergo exercise training at this intensity for a period of three months. Tests and analyses of relevant indicators will be conducted on subjects in all four groups before and after the intervention. The exercise load experiments will be performed on a cycle ergometer.
Interventions
OTHERCOP exercise
crossover point intensity exercise
Sponsors
Beijing Sport University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Age
45 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
* Postmenopausal women without cardiovascular disease
Exclusion criteria
* Women with undetermined menopause * BMI \<18.5 kg/m2 or BMI \>28 kg/m2 * fasting plasma triglyceride levels ≥500 mgdl * diabetes mellitus or fasting glucose \>140 mgd * blood creatinine \>2.0 mgdl * uncontrolled hypertension (systolic blood pressure \>160 mmHg and/or diastolic blood pressure \>110 mmHg) * untreated thyroid disease * life-threatening illness with a prognosis of \<5 years; * history of deep vein thrombosis, * pulmonary embolism, or breast cancer; * currently receiving estrogen therapy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Brachial Artery Flow-Mediated Dilation | 12 weeks | The changes in brachial artery flow-mediated dilation are assessed at three time points: before the intervention, after the acute exercise, and three months following the intervention. |
| Carotid Intima-Media Thickness | 12 weeks | The change of Carotid Intima-Media Thickness before and after intervention. |
| Carotid Diameter | 12 weeks | The change of Carotid Diameter before and after intervention. |
| Carotid End-Diastolic Velocity | 12 weeks | The change of Carotid End-Diastolic Velocity before and after intervention. |
| Carotid Peak Systolic Velocity | 12 weeks | The change of Carotid Peak Systolic Velocity before and after intervention. |
| Pulsatility Index | 12 weeks | The change of Pulsatility Index before and after intervention. |
| Resistive Index | 12 weeks | The change of Resistive Index before and after intervention |
| Brachial-Ankle Pulse Wave Velocity | 12 weeks | The change of Brachial-Ankle Pulse Wave Velocity before and after intervention. |
| Ankle-Brachial Index | 12 weeks | The change of Ankle-Brachial Index before and after intervention. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Serum Reduced Glutathione level | 12 weeks | The change of Serum Reduced Glutathione before and after intervention |
| Oxidized Glutathione level | 12 weeks | The change of Oxidized Glutathione before and after intervention |
| Calculate GSSG/GSH Ratio | 12 weeks | The change of Calculate GSSG/GSH Ratio before and after intervention |
| Serum Soluble Vascular Cell Adhesion Molecule-1 level | 12 weeks | The change of Serum Soluble Vascular Cell Adhesion Molecule-1 Expression before and after intervention |
| Soluble Intercellular Adhesion Molecule-1 level | 12 weeks | The change of Soluble Intercellular Adhesion Molecule-1 before and after intervention |
| Vascular Endothelial Growth Factor level | 12 weeks | The change of Vascular Endothelial Growth Factor before and after intervention |
| body weight | 12 weeks | The change of body weight before and after intervention |
| body mass index | 12 weeks | The change of body mass index before and after intervention |
| Total Cholesterol level | 12 weeks | The change of Total Cholesterol before and after intervention |
| Triglycerides level | 12 weeks | The change of Triglycerides before and after intervention |
| High-Density Lipoprotein Cholesterol level | 12 weeks | The change of High-Density Lipoprotein Cholesterol before and after intervention |
| Low-Density Lipoprotein Cholesterol level | 12 weeks | The change of Low-Density Lipoprotein Cholesterol before and after intervention |
| Apolipoprotein AI level | 12 weeks | The change of Apolipoprotein AI before and after intervention |
| Apolipoprotein B level | 12 weeks | The change of Apolipoprotein B before and after intervention |
| Lipoprotein(a) level | 12 weeks | The change of Lipoprotein(a) before and after intervention |
| Interleukin 6 level | 12 weeks | The change of Interleukin 6 before and after intervention |
| Estradiol level | 12 weeks | The change of Estradiol before and after intervention |
| Interventricular Septum Thickness in Systole | 12 weeks | The change of Interventricular Septum Thickness in Systole before and after intervention |
| Interventricular Septum Thickness in Diastole | 12 weeks | The change of Interventricular Septum Thickness in Diastole before and after intervention |
| Left Ventricular End-Systolic Diameter | 12 weeks | The change of Left Ventricular End-Systolic Diameter before and after intervention |
| Left Ventricular End-Diastolic Diameter | 12 weeks | The change of Left Ventricular End-Diastolic Diameter before and after intervention |
| Left Ventricular Posterior Wall Thickness in Systole | 12 weeks | The change of Left Ventricular Posterior Wall Thickness in Systole before and after intervention |
| Left Ventricular Posterior Wall Thickness in Diastole | 12 weeks | The change of Left Ventricular Posterior Wall Thickness in Diastole before and after intervention |
| Serum Nitric Oxide level | 12 weeks | The change of serum nitric oxide before and after intervention. |
| Left Ventricular End-Diastolic Volume | 12 weeks | The change of Left Ventricular End-Diastolic Volume before and after intervention |
| Fractional Shortening | 12 weeks | The change of Fractional Shortening before and after intervention |
| Left Ventricular Ejection Fraction | 12 weeks | The change of Left Ventricular Ejection Fraction before and after intervention |
| Stroke Volume | 12 weeks | The change of Stroke Volume before and after intervention |
| Heart Rate | 12 weeks | The change of Heart Rate before and after intervention |
| Early Diastolic Mitral Inflow Velocity | 12 weeks | The change of Early Diastolic Mitral Inflow Velocity before and after intervention |
| Atrial Diastolic Mitral Inflow Velocity | 12 weeks | The change of Atrial Diastolic Mitral Inflow Velocity before and after intervention |
| Ratio of Early to Atrial Diastolic Mitral Inflow Velocity | 12 weeks | The change of Ratio of Early to Atrial Diastolic Mitral Inflow Velocity before and after intervention |
| Cardiac Output | 12 weeks | The change of Cardiac Output before and after intervention |
| NT-proBNP level | 12 weeks | The change of NT-proBNP before and after intervention |
| Left Ventricular End-Systolic Volume | 12 weeks | The change of Left Ventricular End-Systolic Volume before and after intervention |
| Plasma Nitrate level | 12 weeks | The change of plasma nitrate before and after intervention. |
| ERRα mRNA and Protein Expression level | 12 weeks | The change of ERRα mRNA and Protein Expression before and after intervention. |
| PGC1α mRNA Expression level | 12 weeks | The change of PGC1α mRNA Expression before and after intervention |
| PGC1α Protein Expression level | 12 weeks | The change of PGC1α Protein Expression before and after intervention |
| ERα mRNA Expression level | 12 weeks | The change of ERα mRNA Expression before and after intervention |
| ERα Protein Expression level | 12 weeks | The change of Protein Expression before and after intervention |
| p38MAPK mRNA Expression level | 12 weeks | The change of p38MAPK mRNA Expression before and after intervention |
| p38MAPK Protein Expression level | 12 weeks | The change of p38MAPK Protein Expression before and after intervention |
Countries
China
Contacts
Primary ContactPeizhen Zhang
Outcome results
None listed